Novartis AG (NOVN) Given a CHF 83.50 Price Target at Deutsche Bank AG
NOVN has been the subject of several other reports. HSBC Holdings plc set a CHF 90 price objective on Novartis AG and gave the stock a buy rating in a research note on Tuesday, September 19th. UBS AG set a CHF 76 price objective on Novartis AG and gave the stock a neutral rating in a research note on Tuesday, July 18th. Sanford C. Bernstein set a CHF 94 price objective on Novartis AG and gave the stock a buy rating in a research note on Tuesday, July 18th. Kepler Capital Markets set a CHF 87 price objective on Novartis AG and gave the stock a buy rating in a research note on Monday, August 28th. Finally, Societe Generale set a CHF 91 price objective on Novartis AG and gave the stock a buy rating in a research note on Wednesday, July 19th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of CHF 85.17.
Novartis AG (VTX NOVN) traded down 0.59% during midday trading on Wednesday, reaching CHK 83.70. 3,248,241 shares of the company traded hands. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 84.60. The company has a market cap of CHK 196.10 billion and a price-to-earnings ratio of 30.56. The company has a 50-day moving average price of CHK 81.69 and a 200-day moving average price of CHK 79.21.
ILLEGAL ACTIVITY NOTICE: “Novartis AG (NOVN) Given a CHF 83.50 Price Target at Deutsche Bank AG” was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at http://www.mareainformativa.com/novartis-ag-novn-given-a-chf-83-50-price-target-at-deutsche-bank-ag/117852/.
About Novartis AG
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.